PMID- 36584134
OWN - NLM
STAT- MEDLINE
DCOM- 20230103
LR  - 20230112
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 12
DP  - 2022
TI  - Publication bias in pharmacogenetics of adverse reaction to antiseizure drugs: An 
      umbrella review and a meta-epidemiological study.
PG  - e0278839
LID - 10.1371/journal.pone.0278839 [doi]
LID - e0278839
AB  - Publication bias may lead to a misestimation in the association between 
      pharmacogenetic biomarkers (PGx) and antiseizure drug's adverse effects (AEs). We 
      aimed to assess its prevalence in this field. We searched for systematic reviews 
      assessing PGx of antiseizure drug's AEs. For each unique association between a 
      PGx, a drug and its AE, we used the available odds ratio (ORs) to generate 
      corresponding funnel plots. We estimated the prevalence of publication bias using 
      visual inspections and asymmetry tests. We explored the impact of publication 
      bias using ORs adjusted for potential publication bias. Twenty-two associations 
      were available. Our visual analysis suggested a publication bias in five out 
      twenty-two funnel plots (23% [95%CI: 8; 45]). The Egger's test showed a 
      significant publication bias in one (HLA-B*15:02 and phenytoin-induced 
      Stevens-Johnson syndrome or toxic epidermal necrolysis, p = 0.03) out of nine 
      (11% [95%CI: 0; 48]) and the Begg's test in one (HLA-B*15:02 and 
      carbamazepine-induced serious cutaneous reactions, p = 0.02) out of ten (10% 
      [95%CI: 0; 45]) assessable funnel plots. Adjusting for publication bias may 
      reduce by half the ORs of the pharmacogenetics associations. Publication bias in 
      the pharmacogenetic of antiseizure drug's AEs is not uncommon and may affect the 
      estimation of the effect of such biomarkers. When conducting pharmacogenetic 
      studies, it is critical to publish also the negative one.
CI  - Copyright: (c) 2022 Bally et al. This is an open access article distributed under 
      the terms of the Creative Commons Attribution License, which permits unrestricted 
      use, distribution, and reproduction in any medium, provided the original author 
      and source are credited.
FAU - Bally, S
AU  - Bally S
AD  - Laboratoire de Biometrie et Biologie Evolutive UMR5558, Universite Lyon 1, CNRS, 
      Villeurbanne, France.
FAU - Cottin, J
AU  - Cottin J
AD  - Service Hospitalo-Universitaire de Pharmacotoxicologie, Pole de Sante Publique, 
      Hospices Civils de Lyon, Lyon, France.
FAU - Gagnieu, M C
AU  - Gagnieu MC
AD  - Laboratoire de Pharmacologie, Groupement Hospitalier Sud, Hospices Civils De 
      Lyon, Lyon, France.
FAU - Lega, J C
AU  - Lega JC
AD  - Laboratoire de Biometrie et Biologie Evolutive UMR5558, Universite Lyon 1, CNRS, 
      Villeurbanne, France.
AD  - Service de Medecine Interne et Vasculaire, Hopital Lyon Sud, Hospices Civils de 
      Lyon, Lyon, France.
FAU - Verstuyft, C
AU  - Verstuyft C
AD  - CESP, MOODS Team, INSERM, Faculte de Medecine, Universite Paris-Saclay, Le 
      Kremlin Bicetre, France.
AD  - Service de Genetique Moleculaire, Pharmacogenetique et Hormonologie de Bicetre, 
      Hopitaux Universitaires Paris-Sud, Assistance Publique-Hopitaux de Paris, Hopital 
      de Bicetre, Le Kremlin Bicetre, France.
FAU - Rheims, S
AU  - Rheims S
AD  - Department of Functional Neurology and Epileptology, Hospices Civils de Lyon, 
      Lyon 1 University, Lyon, France.
FAU - Lesca, G
AU  - Lesca G
AD  - Service de Genetique, Groupement Hospitalier Est, Hospices Civils De Lyon, 
      Universite Lyon 1, Lyon, France.
FAU - Cucherat, M
AU  - Cucherat M
AUID- ORCID: 0000-0003-2150-5932
AD  - Laboratoire de Biometrie et Biologie Evolutive UMR5558, Universite Lyon 1, CNRS, 
      Villeurbanne, France.
AD  - Service Hospitalo-Universitaire de Pharmacotoxicologie, Pole de Sante Publique, 
      Hospices Civils de Lyon, Lyon, France.
FAU - Grenet, Guillaume
AU  - Grenet G
AUID- ORCID: 0000-0002-5237-2581
AD  - Service Hospitalo-Universitaire de Pharmacotoxicologie, Pole de Sante Publique, 
      Hospices Civils de Lyon, Lyon, France.
LA  - eng
PT  - Journal Article
DEP - 20221230
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (HLA-B Antigens)
SB  - IM
MH  - Humans
MH  - Publication Bias
MH  - *Pharmacogenetics
MH  - Systematic Reviews as Topic
MH  - HLA-B Antigens
MH  - Epidemiologic Studies
MH  - *Stevens-Johnson Syndrome
PMC - PMC9803138
COIS- I have read the journal's policy and the authors of this manuscript have the 
      following competing interests: SB, JC, MGC, GG declare that they have no 
      competing interest. JCL has received speaker fees and honoraria from Roche. CV 
      has received consulting fees from Genzyme, Novartis and speaker honoraria from 
      Galapagos. SR received speaker and/or consulting fees from UCB Pharma, EISAI, GW 
      Pharma, Idorsia, LivaNova, and Arvelle Therapeutics. GL has received speaker 
      honoraria from GWpharma, Eisai and Biomarin. MC has received consulting fees from 
      Boehringer Ingelheim, SANOFI, AstraZeneca, EISAI and speaker honoraria from 
      SANOFI. This does not alter our adherence to PLOS ONE policies on sharing data 
      and materials.
EDAT- 2022/12/31 06:00
MHDA- 2023/01/04 06:00
PMCR- 2022/12/30
CRDT- 2022/12/30 13:54
PHST- 2021/06/22 00:00 [received]
PHST- 2022/11/23 00:00 [accepted]
PHST- 2022/12/30 13:54 [entrez]
PHST- 2022/12/31 06:00 [pubmed]
PHST- 2023/01/04 06:00 [medline]
PHST- 2022/12/30 00:00 [pmc-release]
AID - PONE-D-21-20495 [pii]
AID - 10.1371/journal.pone.0278839 [doi]
PST - epublish
SO  - PLoS One. 2022 Dec 30;17(12):e0278839. doi: 10.1371/journal.pone.0278839. 
      eCollection 2022.